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Abstract
Sclerosing mesenteritis (SM) is a rare pathological condition affecting the mesentery. It is a benign, non-specific
inflammation of the adipose tissue of the mesentery of the small intestine and colon. It is characterized by a
variable amount of chronic fibrosis. Its etiology is unknown, the pathogenesis is obscure, while the pathological
characteristics of the disease are unspecific. The initial clinical presentation varies from typically asymptomatic to
that of an acute abdomen. The diagnosis is suggested by computed tomography but is usually confirmed by
surgical biopsies. Treatment is largely empirical; it is decided upon on the basis of the clinical condition of the
patient, and usually a few specific drugs are used. Surgical resection is sometimes attempted for definitive therapy,
although the surgical approach is often limited. We will present five cases of SM as well as a review of the
available literature in order to state and compare a variety of clinical presentations, diverse possible etiologies and
dissimilar treatment options.
Introduction
Sclerosing mesenteritis (SM) is a rare, non-specific,
benign and chronic fibroinflammatory disorder of
unknown etiology that primarily affects the small bowel
mesentery. It usually involves the root of the small
bowel mesentery, but it can also involve the mesocolon,
the peripancreatic and omental fat, and infrequently the
retroperitoneal or pelvic fat [1-6]. The first known series
was published in 1924 [2,7]. In that series the disease
was described under the names of “retractile mesenteri-
tis” and “mesenteric sclerosis”. Since then these terms
have undergone serious elabo r a t i o no nt h eb a s i so ft h e
predominant histology in order to better describe the
disease, including mesenteric lipodystrophy (predomi-
nantly fatty degeneration and necrosis), mesenteric pan-
niculitis (marked chronic inflammation) and retractile
mesenteritis or mesenteric fibrosis (predominant fibro-
sis) [4,6]. Furthermore, mesenteric Weber-Christian dis-
ease, liposclerotic mesenteritis, lipomatosis and
lipogranuloma of the mesentery are numerous other
names that have been used to describe the disease [8].
Emory et al in 1997 [1], after a thorough review of 84
cases concluded that all this uncertainty is partly due to
the variable histological features of a single pathological
entity characterized by a non-specific inflammatory pro-
cesses in the mesenteric fat, that may ultimately lead to
retraction and fibrosis. This varied terminology has
caused considerable confusion, but the condition can
now be evaluated as a single disease with two pathologi-
cal subgroups. When inflammation and fatty necrosis
are predominant components of the process, it is called
“mesenteric panniculitis”, while if fibrosis and retraction
are the principals components, it is called ‘’retractile
mesenteritis’’. The overall presence of some degree of
fibrosis makes the pathological term “sclerosing mesenteri-
tis” the most accurate and preferred term in most cases
[1]. More than 250 cases have been reported in world lit-
erature [9-12] and are often diagnosed incidentally, while
SM shows a 0, 6% prevalence in patients undergoing
abdominal computed tomography (CT) for various rea-
sons [13]. The rarity of this condition has restricted the
ability to record demographic and clinical features, natural
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any medium, provided the original work is properly cited.history and response of the disease to therapy. Thus, treat-
ment decisions are guided by anecdotal/empirical experi-
ence and small case studies. Various drugs, including
corticosteroids, immunosuppressives, colchicine, tamoxi-
fen, progesterone, and recently thalidomide have been
used with varying success [14-17].
Case 1
An 82-year-old female patient was admitted to our hos-
pital with a six month history of recurrent left-sided
abdominal pain, mainly located at the left hypochon-
drium, bloating and nausea. Her past medical history
included rheumatoid arthritis under prednisolon and
methotrexate. These medications had been ceased 9
months earlier due to anemia. Since then she had not
taken any drugs. She had no known allergies, no signifi-
cant family history and a review of her systems was
unremarkable. Upon physical examination the patient
had diffuse abdominal pain in the left abdomen. Deep
palpation of the abdomen revealed an ill-defined mass
located at the left upper abdominal quadrant. Her
laboratory profile was normal. Abdominal x-ray did not
reveal any signs of ileus. Abdominal computed tomogra-
phy (CT) was performed after oral and intravenous con-
trast administration, which showed a focal increase in
density of the mesenteric fat with stranding in the
supra-umbilical and left hypochondrium regions, which
was most probably inflammatory in origin and sugges-
tive of mesenteric panniculitis (Figure 1). Diverticulosis
of the sigmoid colon was noted as well. The patient
underwent a gastroscopy and an enteroclysis. No
intraluminal abnormalities were observed. Colonoscopy
showed only the diverticulosis.
The patient was started on prednisone 40 mg daily.
Her symptoms gradually decreased in intensity and she
commenced eating four days later without any nausea.
She was discharged 7 days after admission with a
recommendation to restart her previous anti-rheumatoid
treatment. She was closely followed-up for 8 months.
Methothraxate was restarted 30 days later. A CT scan
was repeated 3 months later demonstrating a slight ima-
ging improvement although not corresponding to the
important clinical amelioration of the pain that totally
disappeared during this period of time.
Case 2
A 62-year-old male patient presented to us because of a
large incisional abdominal wall hernia. Upon physical
examination, apart from the obvious hernia, there was a
sizable, mobile hard mass located at the mesogastrium
and at the same level as the hernia. The patient did not
mention any abdominal pain, no change in bowel habits
or hematochesia and no weight loss. His past medical
history was unremarkable.
During operation, after identification of the hernia sac,
just beneath the peritoneum, a sizable multinodular
mass was palpated. A thick a n dh a r dm e s e n t e r i u mw a s
revealed presenting with multiple yellowish nodules.
Biopsies of these mesenteric nodules were obtained.
Closure was performed with a biological mesh. All
pathology specimens revealed fatty necrosis with fibrosis
consistent with sclerosing mesenteritis but no evidence
of malignancy (Figures 2, Figure 3).
The patient’s postoperative course was uneventful. He
was mobilized immediately without any special need for
analgesics. He was discharged on the third postoperative
day. The patient was given strict recommendation for
Figure 1 Axial contrast enhanced CT demonstrates a well
marginated fat attenuation of the mesentery surrounding the
mesenteric vessels. A halo of fat is preserved around the
mesenteric vessels and nodules. The lesion is closely related to the
adjacent opacified small bowel which is peripherally displaced. The
fatty mass is delineated by a hyperdense stripe and accompanied
by multiple small nodules.
Figure 2 Idiopathic retractile mesenteritis illustrating fat
necrosis, sclerosing fibrosis and chronic inflammation.
Vlachos et al. International Archives of Medicine 2011, 4:17
http://www.intarchmed.com/content/4/1/17
Page 2 of 9reexamination after a month. When he came back for
reevaluation, he did not report any abdominal pain or
discomfort. An abdominal CT scan was performed in
order to obtain a ‘reference’ image study for his diseases.
The CT scan demonstrated characteristic findings of
sclerosing mesenteritis (diffuse haziness and increased
density of a thickened jejunal mesentery) (Figure 4).
Due to lack of any symptoms it was not considered
necessary to start any immunosuppressive medication.
Additional CT scan was not proposed since the patient
does not present clinical acute or chronic worsening of
the disease. The patient is doing well 11 months later.
Case 3
A 72-year-old female patient was admitted to our hospi-
tal with a three day history of recurrent abdominal pain.
On clinical examination the patient appeared ill, she was
febrile (38°C), in acute distress and reporting diffuse
abdominal pain. There was a large movable mass pal-
pated, extending from the pubis to the umbilicus. The
p a t i e n td i dn o tr e p o r ta n yr e c e n tw e i g h tl o s sa n dw a s
passing flatus and stools. She had a past medical history
suggestive of Dukes B sigmoid colon cancer which had
been excised 36 months previously. Abdominal X-ray
did not reveal any pathology, while her laboratory pro-
file was normal.
The patient had a colonoscopy which revealed no can-
cer recurrence or any other pathology in the remaining
colon. Axial contrast enhanced CT image of the mid
abdomen showed a heterogeneous fibrofatty mass within
the root of the mesentery, a finding consistent with
sclerosing mesenteritis (Figure 5).
Conservative treatment was commenced based on corti-
costeroids. The patient was started on high dose steroid
therapy (methylprednisone, 80 mg iv, every 8 hours). She
experienced rapid clinical improvement. She was dis-
charged from the hospital 4 days later with a marked ame-
l i o r a t i o no nar e g i m e no fo r a lp r e d n i s o n e( 4 0m g / d a y ) .
Prednisone was gradually interrupted after 12 weeks. Her
pain gradually decreased, and 6 months later had
no abdominal complaints. No additional CT scan was pro-
posed. However, we emphasized the need of close observa-
tion of the disease in the context of her regular oncologic
follow-up.
Case 4
An 83-year-old man was admitted to our department for
surgical treatment of cecal cancer that had been diagnosed
elsewhere. He had a past medical history of atrial fibrilla-
tion and coronary heart disease, both on medication. He
mentioned having undergone an appendicectomy in his
Figure 3 Idiopathic retractile mesenteritis illustrating fat
necrosis, sclerosing fibrosis and chronic inflammation.
Figure 4 Diffuse haziness and increased density of a thickened
jejunal mesentery. There is smooth displacement of the adjacent
bowel loops. The mesenteric vessels course through the lesion
without distortion.
Figure 5 Axial contrast enhanced CT image of the mid
abdomen shows a heterogeneous fibrofatty mass within the
root of the mesentery containing a focus of calcification.
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earlier. Three months earlier, due to persistent fatigue, he
had undergone a complete laboratory examination
demonstrating iron deficiency anemia which was treated
with oral ferum. Because of continuing weight loss,
abdominal discomfort and particularly because of a non
symmetric sizable palpable mass of the middle abdomen,
he underwent CT of the abdomen. The CT revealed cecal
thickness and radiological findings of sclerosing mesenteri-
tis. Colonoscopy revealed a cecal mass.
At laparotomy a diffusely thick mesenterium with
multiple yellowish nodules was identified (Figure 6). A
right hemicolectomy was performed, and multiple biop-
sies of the mesenteric nodules were obtained. The
pathology report described a Astler-Coller C2 cecal ade-
nocarcinoma and diffuse sclerosing mesenteritis of the
excised mesenterium. Two months later, he followed
oncologic treatment consisting in capecidabine under
close surveillance of his coagulation parameters. No
abdominal pain or discomfort was observed during this
period. CT image, performed 6 months later in the con-
text of cancer follow up did not demonstrate important
radiologic changes of the sclerosing mesenteritis.
Case 5
A 79-year-old woman presented to the outpatient facil-
ities because of a chronic history of recurrent abdominal
pain. Her symptoms were episodic and included discom-
fort and nausea resulting in pain that lasted a few
minutes. Since last month the pain was more intense,
lasted longer periods and was relieved only with large
doses of non steroid anti-inflammatory drugs. Upon
physical examination she appeared well-looking, was in
no acute distress and had stable vital signs. A palpable,
rather painful firm abdominal mass was identified in the
umbilical area.
Laboratory data revealed a normal complete blood
count, blood chemistry and coagulation profile. Upper
gastrointestinal endoscopy was performed and showed
mild non-erosive gastritis and interspersed gastric
nodules which the pathology report showed to be non
malignant after they have been biopsied. She underwent
an abdominal CT which showed a fatty mass within the
small bowel mesentery surrounded by nodules and stric-
tures. Such radiological findings were not indicative of a
specific diagnosis, thus an exploratory laparotomy was
performed in order to definitely exclude any malignancy.
The mass was biopsied, however, a complete removal
was impossible due to its encasement of the superior
mesenteric vessels. The patient’s postoperative course
was uneventful. Pathology examination proved to be dif-
ficult because of multiple lymph nodes found in the spe-
cimen which initially presented with characters of small
B-cells lymphoma. The later was excluded with poly-
merase chain reaction (PCR). A diagnosis of sclerosing
mesenteritis was finally established (Figures 7, 8).
The patient was treated with steroids (prednisone 40
mg/daily). Clinical improvement was evident after six
Figure 6 A diffusely thick mesenterium with multiple yellowish nodules.
Vlachos et al. International Archives of Medicine 2011, 4:17
http://www.intarchmed.com/content/4/1/17
Page 4 of 9weeks, while four months later, the patient was symp-
tom free. Six months later a CT was performed demon-
strating an important amelioration of the radiologic
appearance of the mesenteric fat.
Discussion
Sclerosing mesenteritis is a rare disease of unknown
pathogenesis represented with a various and non specific
symptomatology that has become of clinical interest
during recent years. Only four large series have been
published in world literature, one by Durst [18], one by
Kipfer [19], one by Emory [1], and the largest one more
recently by Akram [10]. Other than these four series,
most published reports are of single patients or small
case series like ours [15,20-22], or reviews of existing lit-
erature [23-25]. Due to the rareness of published cases
there is a lack of established knowledge about the exact
cause, the etiological factors, the natural history, the
prognosis, and finally the optimal treatment options of
patients with SM.
SM is a disease of middle-aged or older adults (age
range 20-90 years), primarily diagnosed during the 6
th
to 7
th decade of life; the incidence increases with age,
while pediatric cases are very uncommon, probably
because children have less mesenteric fat than adults
[10,26,27]. Most studies indicate that the disease appears
to be at least twice as common in men as in women
[1,18,19].
In over 90% of cases SM involves the small-bowel
mesentery, but it may sometimes involve the sigmoid
mesentery [28]. Exceptionally it may involve the meso-
colon, peripancreatic region, omentum, retroperitoneum
or pelvis [10].
The pathophysiology of SM remains unknown. The
pathogenic mechanism seems to be a non-specific
response to a wide variety of stimuli. It has been
reported on in one series in which 84% of patients had
a history of previous abdominal trauma or surgery [1].
In a recent study, Akram et al reported a history of
abdominal surgery in about 40% of the patients [10].
Most of these patients had had cholecystectomy or
appendicectomy between 1960 and 1990, in an era
where no laparoscopic procedures had yet been devel-
oped. Before 1990 the use of powdered surgical gloves
was a common practice; this fact might have a role in
the formation of peritoneal adhesions and fibrosis in
some cases [10,29]. Autoimmune and infective causes
such as abdominal tuberculosis [9] as well as vascular
insufficiency (mesenteric thrombosis, mesenteric arterio-
pathy, previous surgery, trauma) and retained suture
material [1,11,13] have all been implicated as etiological
factors. Other factors, such as coronary disease, gall-
stones, cirrhosis, peptic ulcer, chylous ascitis or abdom-
inal aortic aneurysm have also been associated with this
disease [27]. A recent study has shown a strong relation-
ship between tobacco consumption and SM [13]. Addi-
tionally, SM is often associated with other idiopathic
inflammatory disorders such as retroperitoneal fibrosis,
sclerosing cholangitis, Riedel’s thyroiditis and orbital
pseudotumours [30-32].
Sclerosing mesenteritis has been associated with a
variety of malignant diseases such as lymphoma, colon
cancer, renal cell cancer, lung cancer, melanoma, mye-
loma, gastric carcinoma, Hodgkin’s disease, chronic lym-
phocytic leukemia, thoracic mesothelioma and carcinoid
tumor [1,26,13,28]. Kipfer et al. [19] found that 30% of
patients with SM had an underlying malignancy. Daska-
logiannaki et al. [13] reported a higher rate of coexisting
malignancy (69%), most commonly urogenital malignan-
cies and gastrointestinal adenocarcinoma or lymphoma.
Figure 7 Fatty necrosis with scarce fibrotic components,
adipose cells with foamy cytoplasm and infiltration of
numerous lipid-laden macrophages.
Figure 8 Reactive lymphadenopathy of the mesenteric lymph
nodes with expansion and alteration of the marginal zone, but
without effacement of the node architecture.
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prevalence of malignancy in SM is no different from the
general population of patients undergoing CT for var-
ious reasons [30]. It seems that the exact pathogenetic
link between SM and malignant disease is unclear. The
possibility of SM representing a paraneoplastic response
has been suggested [13,31].
In our series 2 out of the 5 patients (40%) had colon
cancer. Nevertheless, case 3 patient had excised the sig-
moid cancer 36 months prior to his admission for SM
symptoms, and unfortunately we do not have any infor-
mation regarding the mesenteric condition in her pre-
vious surgery. Two patients (40%) had a free medical
history; thus we were not able to link their disease with
any potential pathogenetic factor. One patient had a his-
tory of rheumatoid arthritis under immunosuppressant
treatment with prednisone and methotrexate for several
years. The abnormal immunoreactions common in auto-
immune diseases could cause an inflammatory mesen-
teric process. The interruption of the
immunosuppressive therapy probably favored the clini-
cal presentation of the disease that had been covered
during treatment.
The disease is often asymptomatic and indeed most
patients in any given series were incidentally identified
during a CT examination [13]. When present, clinical
symptoms are non-specific and protean. The most com-
mon symptoms are abdominal pain, bloating/distension,
diarrhea, nausea, vomiting, weight loss, loss of appetite,
constipation and altered bowel habit [10]. Most symp-
toms associated with SM are caused by the direct
mechanical effect of the mesenteric mass encasing the
bowel, blood vessels and lymphatics, resulting in abdom-
inal pain, bowel obstruction, ischemia and chylous
ascites. Exceptionally, rectal bleeding, jaundice, gastric
outlet obstruction, fever of unknown origin, autoim-
mune haemolytic anaemia, protein-losing enteropathy
and even acute abdomen have been reported
[1,10,33,34]. Upon physical examination the abdomen
may be normal or there may be tenderness. Abdominal
mass may be palpated in a proportion of patients that
varies from study to study. Durst et al [18] report an
incidence of a palpable mass of 50%, while Akram et al
[10] found a significantly lower number (15%) of
patients suffering from SM having a mass. Such a wide
variety of signs and symptoms means that a large num-
ber of pathological conditions must be considered for
differential diagnosis; lymphoma, lymphosarcoma, des-
moid tumors, carcinoid tumors, peritoneal mesothe-
lioma, amyloidosis, retroperitoneal sarcoma, infectious
diseases (tuberculosis, histoplasmosis), reaction to adja-
cent cancer or chronic abscess, chronic inflammation
due to foreign body and Whipple’s disease should be
part of the differential diagnosis of SM.
The diverse clinical presentation of SM was obvious in
our series as well. There were two asymptomatic
patients that were accidentally diagnosed as having SM
during surgery for an abdominal hernia and cecal cancer
respectively. The weight loss reported by one patient
could not be attributed to the SM as there was an
underlying malignant disease (cecal cancer). The other
three patients presented with abdominal pain as the pre-
dominant symptom, while there was one patient with
fever. It is remarkable that during physical examination,
a palpable mass was revealed in all of the patients
(100%).
Blood tests tend to be within the normal range. Neu-
trophilia, elevated erythrocyte sedimentation rate or
anaemia have been reported occasionally in SM, but
these are not specific [13,26]. While a definite diagnosis
of SM requires surgical excision biopsy and pathological
analysis, in the majority of cases the disease is diagnosed
predominantly on the basis of CT features. In one study
only 8% of patients had a biopsy proven diagnosis of
SM [13]. On CT the hallmark of SM is increased density
of mesenteric fat to attenuation values of -40 to -60
Hounsfield units (HU) as compared to the attenuation
of normal subcutaneous and retroperitoneal fat of -100
to -160 HU [13]. CT scan appearance varies from
increased attenuation ("misty mesentery”) to solid soft-
tissue mass, which might envelope the mesenteric ves-
sels preserving the surrounding fatty area ("fat ring
sign”) [32]. The hyperattenuating fat encases the mesen-
teric vessels but does not displace them. Multiple
masses or diffuse thickening of the mesentery are less
common [3]. The mesenteric lesion may occasionally
displace the adjacent small bowel loops. Calcifications
associated with fat necrosis are a rare finding in this dis-
ease. In 50% of patients a tumoural pseudocapsule may
be present [3,13] The small bowel mesentery is affected
in most cases especially at its root; with a propensity for
jejunal mesentery, but sigmoid mesocolon and omentum
can occasionally be involved [30]. Exceptionally, the
inflammatory process may extend into the retroperito-
neum and involve the pancreas, duodenum, inferior
vena cava, urinary system and pelvis [3,18]. SM may
mimic imaging features of pancreatitis or even a pan-
creatic mass with retroperitoneal extension [6,35]. In
80% of patients with SM small soft tissue nodules can
be found scattered within the mesenteric mass. These
nodules are usually less than 5 mm in diameter and are
thought to represent small lymph nodes [13,32]. In the
study of Akram et al [10], in 61% of cases, the abdom-
i n a lC Ts h o w e das i n g l es o f t - t i s s u em a s si nt h er o o to f
the mesentery, often containing calcification. In 34% of
cases there was a subtle increase in the density of the
mesenteric fat suggesting mild mesenteric fibrosis or
inflammation. Small retroperitoneal and/or mesenteric
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lateral circulation were frequently noted. SM has also
been reported to have CT findings that show similar
radiological appearance to other conditions including
desmoid tumors, lipoma, lymphoma, carcinoid tumors,
liposarcoma, tuberculosis, mesothelioma, mesenteric
metastases, edema or hematoma [36,37].
A part from CT, magnetic resonance imaging (MRI)
seems to be helpful in the detection of SM [38]. PET-
CT has been proposed to have a promising role in dif-
ferentiating between benign SM and co-existing SM and
mesenteric tumoural involvement particular in patients
with lymphoma [8].
In our cases, four patients underwent a CT scan in an
effort to establish a diagnosis. CT was a valuable tool in
excluding abdominal pathology that might need urgent
surgical intervention. In addition, in two cases it was the
CT findings that suggested the conservative/medical
treatment as the therapeutic option of choice. Neverthe-
less CT findings cannot distinguish the severity of the
disease.
Histologically, sclerosing mesenteritis displays different
stages of involvement [26]. The first stage involves
mesenteric lipodystrophy in which a layer of foamy
macrophages replaces the mesenteric fat. Signs of acute
inflammation are absent or minimal; the disease tends
to be clinically asymptomatic and prognosis is good. In
the second stage, termed mesenteric panniculitis histol-
ogy reveals an infiltrate made up of plasma cells and a
few polymorphonuclear leukocytes, foreign-body giant
cells and foamy macrophages. Most common symptoms
include fever, abdominal pain and malaise. The final
stage is retractile mesenteritis which is distinguished by
collagen deposition and a diffuse presence of necrosis
and fibrosis that contribute to tissue retraction. Collagen
deposition leads to scarring and retraction of the mesen-
tery which in turn leads to the formation of abdominal
masses and obstructive symptoms. The exact diagnosis
is often difficult and is usually made by finding one of
three major pathological features; fibrosis, chronic
inflammation or fatty infiltration of the mesentery. To
some extent all three components are present in most
cases. This pathological lesion involves the mesenteric
and submucosal fat of the small bowel often with exten-
sion into the bowel muscle and submucosa. However
the mucosa usually remains intact [32].
A large series by Kipfer et al [19], and Akram et al
[10] reported that 74% and 50% respectively of patients
underwent surgical exploration in order to establish a
diagnosis. With better non-invasive/imaging diagnostic
methods fewer patients require exploratory surgery
unless indicated by intractable complications of SM
(small bowel obstruction, superior mesenteric venous
thrombosis, lower gastrointestinal bleeding), or if there
is high clinical suspicion of an alternative diagnosis.
However attempted surgical resection or debulking
usually does not result in resolution of the symptoms or
prevent disease progression as evidenced by only 10% of
our patients improving after surgery alone [10].
There is no consensus of opinion on medical treat-
ment for symptomatic cases of SM. A variety of anti-
inflammatory, immunomodulatory, and antifibrotic
agents are used. Drug therapy is not standardized and
should be based on the stage of the disease. In the first
stage (lipodystrophy) when fat necrosis is predominant,
authors agree not to treat the disease as it can regress
spontaneously. Chronic inflammation requires therapy
based on corticosteroids and various types of immuno-
suppressants. Good results are reported on with cyclo-
phosphamide, colchicine, azathioprine, thalidomide, and
also with oral progesterone and tamoxifen
[10,11,17,34,39,40]. Pentoxyfylline has been recently
reported as promising antifibrotic agent successfully
used in a case of sclerosing mesenteritis [41]. Tamoxifen
was successfully used in 19 patients in the series of
Akram et al. [10] and 63% of these patients responded
within 12 weeks of initiation of treatment. In the same
series no similar benefits were obtained with prednisone
alone or in combination with non-tamoxifen treatment.
In contrast, clinical improvement was observed with
oral corticosteroid treatment alone in two patients of
our small series. As intense fibrosis appears bowel
obstruction may occur. Intestinal resections, bypasses or
neostomy might be required.
In the first case of our series the combined use of cor-
ticosteroids and methotrexate against rheumatoid arthri-
tis probably maintained SM in a tolerant state. When
this balance was interrupted, the disease brought out its
clinical manifestations. As soon as the patient restarted
the immunosuppressive treatment for rheumatoid
arthritis she had a marked clinical improvement.
Although, it is not clear if the clinical benefit was due to
cortisone, methothrexat or a synergic effect of both. In
case 2, treatment was not administered because there
were no specific symptoms. In case 4, additional oncolo-
gic treatment was added and one could await an anti-
proliferative and immunosupressive effect. However, no
particular radiologic changes were observed. In case 3
and 5, conservative treatment was commenced based on
corticosteroids. The patients experienced rapid clinical
improvement. In these cases steroid therapy gave very
satisfactory results, therefore it was not necessary to use
any other medications. We should also emphasize that
CT scan was repeated in three cases (case 1, 4, 5). Parti-
cular amelioration of the radiologic findings was
observed only in one case. However, all patient pre-
sented important clinical improvement. This fact is in
contrast with other reported cases where therapy was
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al [10] consider that the management of the disease
should be based on severity and type of symptoms and
not on CT findings. The author does not recommend
serial CT follow-up, unless clinical deterioration is
observed. Our data further support this opinion.
It seems that SM has different modes of progression, a
complete or partial resolution, a non progressive course
with stable clinical symptoms that can be controlled
with drugs and a progressive course that may be fatal
[39,40]. Nevertheless, the disorder has generally been
reported as having a self- limiting benign course with
spontaneous remissions being the most favourable out-
come. Although the overall prognosis is good, in about
20% of patients, SM is associated with significant mor-
bidity and a chronic debilitating course [16].
Conclusions
Sclerosing mesenteritis is a rare idiopathic disorder that
involves predominantly the small bowel mesentery with
varying degrees of fibrosis, inflammation and fat necrosis.
Diagnosis of this nonspecific benign inflammatory dis-
ease is a challenge to surgeons, radiologists, gastroenter-
ologists and pathologists. Its clinical presentation is quite
diverse and ranges from being asymptomatic to a debili-
tating disease. CT features of the disease, usually highly
suggestive, have recently been delineated clearly.
Approximately half of the patients may not require any
treatment. However, in symptomatic cases treatment
should be tailored according to the severity and type of
individual symptoms. Patients with SM related complica-
tions like intractable bowel obstruction should undergo
surgery, while those with nonobstructive symptoms
might benefit from steroid therapy alone or in combina-
tion with other drugs. Overall prognosis is usually good
and recurrence seems to be rare. However long-term fol-
low-up is needed to document these results.
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